Cargando…

The best drug supplement for obesity treatment: a systematic review and network meta-analysis

BACKGROUND: Obesity is a complex disease with an increasing prevalence worldwide. There are different weight-management options for obesity treatment, including dietary control, exercise, surgery, and medication. Medications are always associated with different responses from different people. More...

Descripción completa

Detalles Bibliográficos
Autores principales: Salari, Nader, Jafari, Samira, Darvishi, Niloofar, Valipour, Elahe, Mohammadi, Masoud, Mansouri, Kamran, Shohaimi, Shamarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522222/
https://www.ncbi.nlm.nih.gov/pubmed/34663429
http://dx.doi.org/10.1186/s13098-021-00733-5
_version_ 1784585049123848192
author Salari, Nader
Jafari, Samira
Darvishi, Niloofar
Valipour, Elahe
Mohammadi, Masoud
Mansouri, Kamran
Shohaimi, Shamarina
author_facet Salari, Nader
Jafari, Samira
Darvishi, Niloofar
Valipour, Elahe
Mohammadi, Masoud
Mansouri, Kamran
Shohaimi, Shamarina
author_sort Salari, Nader
collection PubMed
description BACKGROUND: Obesity is a complex disease with an increasing prevalence worldwide. There are different weight-management options for obesity treatment, including dietary control, exercise, surgery, and medication. Medications are always associated with different responses from different people. More safety and efficacy of drugs with fewer side effects are valuable for any clinical condition. In this systematic review and network meta-analysis, different anti-obesity drugs are compared to identify the most effective drug. METHODS: All relevant studies were extracted by searching national and international databases of SID, MagIran, ProQuest, PubMed, Science Direct, Scopus, Web of Science (WoS), and Google Scholar without time limit until October 2020. Finally, the meta-analysis was performed with the 11 remaining studies containing 14 different drug supplements. The standardized mean difference (SMD) was calculated at a 95% confidence interval (CI) to evaluate the effects of each treatment group compared with placebo. A random-effect model was used to evaluate the effect of individual studies on the final result. Heterogeneity and incompatibility of the network were assessed by Cochran’s Q and Higgins I(2), and the Net Heat chart, respectively. Data analysis was performed using R software. RESULTS: Our results showed that there were significant mean effects in people intervened with Phentermine 15.0 mg + Topiramate 92.0 mg, Phentermine 7.5 mg + Topiramate 46.0 mg, Pramlintide, Naltrexone + Bupropion 32, and Liraglutide, with SMD effects size = − 9.1, − 7.4, − 6.5, − 5.9, − 5.35, respectively. CONCLUSION: This study was performed to compare the effect of different drugs used for weight loss in obese patients. The most effective drugs for weight loss were phentermine and topiramate, pramlintide, naltrexone, bupropion, and liraglutide compared to placebo treatment, respectively. This study provides new insights into anti-obesity drugs and hopes to shed new light on future research to manage and treat obesity.
format Online
Article
Text
id pubmed-8522222
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85222222021-10-21 The best drug supplement for obesity treatment: a systematic review and network meta-analysis Salari, Nader Jafari, Samira Darvishi, Niloofar Valipour, Elahe Mohammadi, Masoud Mansouri, Kamran Shohaimi, Shamarina Diabetol Metab Syndr Research BACKGROUND: Obesity is a complex disease with an increasing prevalence worldwide. There are different weight-management options for obesity treatment, including dietary control, exercise, surgery, and medication. Medications are always associated with different responses from different people. More safety and efficacy of drugs with fewer side effects are valuable for any clinical condition. In this systematic review and network meta-analysis, different anti-obesity drugs are compared to identify the most effective drug. METHODS: All relevant studies were extracted by searching national and international databases of SID, MagIran, ProQuest, PubMed, Science Direct, Scopus, Web of Science (WoS), and Google Scholar without time limit until October 2020. Finally, the meta-analysis was performed with the 11 remaining studies containing 14 different drug supplements. The standardized mean difference (SMD) was calculated at a 95% confidence interval (CI) to evaluate the effects of each treatment group compared with placebo. A random-effect model was used to evaluate the effect of individual studies on the final result. Heterogeneity and incompatibility of the network were assessed by Cochran’s Q and Higgins I(2), and the Net Heat chart, respectively. Data analysis was performed using R software. RESULTS: Our results showed that there were significant mean effects in people intervened with Phentermine 15.0 mg + Topiramate 92.0 mg, Phentermine 7.5 mg + Topiramate 46.0 mg, Pramlintide, Naltrexone + Bupropion 32, and Liraglutide, with SMD effects size = − 9.1, − 7.4, − 6.5, − 5.9, − 5.35, respectively. CONCLUSION: This study was performed to compare the effect of different drugs used for weight loss in obese patients. The most effective drugs for weight loss were phentermine and topiramate, pramlintide, naltrexone, bupropion, and liraglutide compared to placebo treatment, respectively. This study provides new insights into anti-obesity drugs and hopes to shed new light on future research to manage and treat obesity. BioMed Central 2021-10-18 /pmc/articles/PMC8522222/ /pubmed/34663429 http://dx.doi.org/10.1186/s13098-021-00733-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Salari, Nader
Jafari, Samira
Darvishi, Niloofar
Valipour, Elahe
Mohammadi, Masoud
Mansouri, Kamran
Shohaimi, Shamarina
The best drug supplement for obesity treatment: a systematic review and network meta-analysis
title The best drug supplement for obesity treatment: a systematic review and network meta-analysis
title_full The best drug supplement for obesity treatment: a systematic review and network meta-analysis
title_fullStr The best drug supplement for obesity treatment: a systematic review and network meta-analysis
title_full_unstemmed The best drug supplement for obesity treatment: a systematic review and network meta-analysis
title_short The best drug supplement for obesity treatment: a systematic review and network meta-analysis
title_sort best drug supplement for obesity treatment: a systematic review and network meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522222/
https://www.ncbi.nlm.nih.gov/pubmed/34663429
http://dx.doi.org/10.1186/s13098-021-00733-5
work_keys_str_mv AT salarinader thebestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT jafarisamira thebestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT darvishiniloofar thebestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT valipourelahe thebestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT mohammadimasoud thebestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT mansourikamran thebestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT shohaimishamarina thebestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT salarinader bestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT jafarisamira bestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT darvishiniloofar bestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT valipourelahe bestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT mohammadimasoud bestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT mansourikamran bestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis
AT shohaimishamarina bestdrugsupplementforobesitytreatmentasystematicreviewandnetworkmetaanalysis